“Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: A multicenter phase II trial of the Southern Italy Cooperative Oncology Group”.

Sergio Palmeri, Carlo Putzu, Pasquale Comella, Ettore Greco, Luca Franco, Giacomo Vessia, Vito Lorusso, Silvana Leo, Michele Cannone, Sergio Mancarella, Rossana Casaretti, Luigi Maiorino, Claudia Sandomenico, Bruno Massidda, Mario Roselli

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Purpose: This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer. Methods: Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m 2 iv and irinotecan 150 mg/m2 iv on day 1, 6S-folinic acid 250 mg/m2 iv and fluorouracil 750 mg/m2 iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles. Results: Sixty-three patients were treated, with a median of eight (range 1-12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, 22-46%]). Median progression-free survival was 7.5 (95% CI, 5.6-9.4) months, and median overall survival was 12.1 (95% CI, 10.8-13.4) months. Most common grade ≥3 toxicities were neutropenia (59%), febrile neutropenia (7%), vomiting (20%), and diarrhoea (10%). All-grade neurotoxicity affected 33% of patients. Conclusions: Oxaliplatin, irinotecan, and fluorouracil/folinic acid administered every 2 weeks are safe and active in advanced gastric cancer.
Original languageEnglish
Pages (from-to)893-899
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume64
Publication statusPublished - 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of '“Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: A multicenter phase II trial of the Southern Italy Cooperative Oncology Group”.'. Together they form a unique fingerprint.

Cite this